Eurasian Hematology-Oncology Group

http://www.ehog.net/

 

Navigating Treatment Options for Newly Diagnosed ASCT-Eligible MM in 2021: Induction & Standard (VCD, VTD, VRd, Dara-VTD), Upfront ASCT vs. Bortezomib, Len Maintenance Until Progression

84 views
May 13, 2021
Comments 0
Login to view comments. Click here to Login